AI Magazine Issue 3 2018

6 Acquisition International - Issue 3 2018 Sintetica S.A. is a pharmaceutical company delivering injectable anaesthetics and analgesics to patients worldwide through innovative science and excellence in development, production and marketing. We sat down with Pasquale Mitidieri, Global Markets Corporate Director, who gives us an insight into the success of the firm and its achievements. stablished 1921 in Switzerland, Sintetica possess sites which are based in Switzerland, Germany, Austria, Italy and United Kingdom, with its headquarters in Mendrisio, Switzerland. With 230 people employed around Europe, the workforce is diverse, coming from 28 different countries across the globe. Sintetica’s primary focus is on local anaesthesia and pain relief. As of 2012, Sintetica established its global division, which was the first international corporate structure. The global division was tasked with pursuing international growth under two distinct models, being a B2B licensing strategy and somewhat later a B2C strategy in selected markets. Pasquale goes into detail about the B2B model and what the overall goal of the new corporate structure is for Sintetica. “Under the B2B model, staff sought to license out top brands to partners with whom employees share values. Foremost among these values, people and relationships, including business relationships, come first, and thus Sintetica seeks to build business by finding partners with whom it can share its values. As such, all our partners must meet strict ethical criteria and share our innovation driven ‘quality without compromise’ value proposition. This was the most critical and difficult challenge we have faced since beginning our internationalisation efforts, however I Company: Sintetica S.A. Contact: Pasquale Mitidieri Address: via Penate 5, 6850 Mendrisio, Switzerland Phone: 0041 32 864 93 93 Website: www.sintetica.com Transforming the Pharmaceutical Landscape E 1711AI21 am proud to say that we have been very successful” Focusing on specific subjects, the global division is focusing on high speed robust partner selection and affiliation in every country around the world. It is determined to offer a dynamic portfolio of selected branded medicines, developed to answer unmet clinical needs, to build sustainable and long-lasting alliances. Pasquale is keen to talk about the firm’s rapid ascent and expansion across the globe. “Across the country, we have built an agile and multicultural high-performing division to support rapid global expansion. Global Division has two sites, one based in the HQs of Mendrisio, Switzerland and the second in Como-Italy, from where all partners worldwide are managed. “A novel structure of highly experienced and qualified alliance managers is covering the entire globe, ensuring a high level proximity support to our business partners to reinforce even more the long lasting fruitful cooperation model.” Pasquale outlines Sintetica’s overall mission, discussing what steps are taken in order to achieve this, and how employees integrate innovation into every aspect of its work. “Here at Sintetica, we are fully committed to innovating therapies and drugs in local anaesthesia, pain management and neuromodulation. As such, we move forward with passion and competence in the full respect of people and the environment. All our efforts and resources are focused on becoming a leader in these fields, by developing novel medicine and better treatment options for physicians and patients worldwide. “To achieve this leadership by innovation in the context of global growth, we consider strategic partnering and business development to be the key factors.” “A novel structure of highly experienced and qualified alliance managers is covering the entire globe, ensuring a high level proximity support to our business partners to reinforce even more the long lasting fruitful cooperation model.”